icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Aug 27-29
Digital ILC 2020
Back grey_arrow_rt.gif
 
 
 
Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis
 
 
  EASL 2020 Aug 29 virtual
 
Stephen A. Harrison1,2, Guy Neff3, Cynthia D. Guy4, Mustafa Bashir5, Nadege Gunn2, Angelo H. Paredes6, Ziad Younes7, Juan P. Frias8, James F. Trotter9, Anita Kohli10, Sam E. Moussa11, Kristin Nelson12, Mildred Gottwald12, William Chang12, Andrew Z. Yan12, Alex M. DePaoli12, Lei Ling12 and Hsiao D. Lieu12
 
1University of Oxford, 2Pinnacle Clinical Research, 3Covenant Research, 4Pathology, Duke University, 5Radiology and Medicine (Gastroenterology), Duke University, 6San Antonio Military Medical Center, 7Gastro One Research, TN, 8National Research Institute, CA, 9Texas Digestive Disease Consultants, TX, 10Arizona Liver Health, AZ, 11Adobe Clinical Research, AZ, 12NGM Biopharmaceuticals, CA

0908201

0908202

0908203

0908204

0908205

0908206

0908207

0908208

0908209

09082010